17.83
price down icon0.89%   -0.16
after-market Dopo l'orario di chiusura: 17.85 0.02 +0.11%
loading
Precedente Chiudi:
$17.99
Aprire:
$17.63
Volume 24 ore:
1.85M
Relative Volume:
2.62
Capitalizzazione di mercato:
$1.62B
Reddito:
$802.20M
Utile/perdita netta:
$-155.20M
Rapporto P/E:
-5.3065
EPS:
-3.36
Flusso di cassa netto:
$-141.30M
1 W Prestazione:
-18.81%
1M Prestazione:
-32.64%
6M Prestazione:
-8.42%
1 anno Prestazione:
+4.76%
Intervallo 1D:
Value
$16.87
$18.17
Intervallo di 1 settimana:
Value
$16.86
$22.91
Portata 52W:
Value
$15.99
$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Name
Nome
Myriad Genetics Inc
Name
Telefono
801-584-3600
Name
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Name
Dipendente
2,700
Name
Cinguettio
@myriadgenetics
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
MYGN's Discussions on Twitter

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-12-21 Ripresa Piper Sandler Neutral
2023-12-19 Iniziato Wells Fargo Equal Weight
2023-12-14 Iniziato Guggenheim Buy
2023-12-13 Iniziato Wolfe Research Outperform
2023-07-05 Ripresa JP Morgan Underweight
2023-05-23 Aggiornamento Goldman Sell → Buy
2023-01-18 Aggiornamento Raymond James Mkt Perform → Outperform
2022-10-06 Iniziato Stephens Equal-Weight
2021-10-15 Ripresa Cowen Market Perform
2021-06-15 Iniziato Raymond James Mkt Perform
2021-06-03 Iniziato Goldman Sell
2019-09-26 Downgrade BofA/Merrill Neutral → Underperform
2019-08-14 Downgrade Piper Jaffray Overweight → Neutral
2019-08-02 Aggiornamento BofA/Merrill Underperform → Neutral
2019-08-01 Aggiornamento Barclays Underweight → Equal Weight
2019-07-29 Downgrade Needham Strong Buy → Hold
2019-07-09 Downgrade Cowen Outperform → Market Perform
2019-03-12 Reiterato Needham Strong Buy
2019-01-03 Iniziato Needham Strong Buy
2018-11-30 Aggiornamento Goldman Sell → Neutral
2018-10-10 Aggiornamento Piper Jaffray Neutral → Overweight
2018-07-11 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-03-21 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2018-01-29 Iniziato Goldman Sell
2018-01-22 Reiterato Barclays Equal Weight
2018-01-05 Iniziato BTIG Research Buy
2017-10-02 Ripresa Leerink Partners Mkt Perform
2017-08-09 Reiterato Barclays Equal Weight
2017-02-08 Aggiornamento Ladenburg Thalmann Sell → Neutral
2017-01-18 Iniziato Deutsche Bank Sell
2016-10-10 Downgrade Ladenburg Thalmann Neutral → Sell
Mostra tutto

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

pulisher
Nov 04, 2024

UnitedHealthcare limits coverage for Myriad's GeneSight test - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%Here's Why - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics Inc (MYGN) Trading Down 3.81% on Nov 4 - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight - MarketWatch

Nov 04, 2024
pulisher
Nov 04, 2024

UnitedHealthcare limits coverage for Myriad's GeneSight test By Investing.com - Investing.com UK

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing - GlobeNewswire

Nov 04, 2024
pulisher
Nov 03, 2024

Trading (MYGN) With Integrated Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

Myriad weakness due to UnitedHealth coverage update, says Stephens - Yahoo Finance

Nov 02, 2024
pulisher
Nov 02, 2024

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge - Simply Wall St

Nov 02, 2024
pulisher
Nov 02, 2024

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment? - Simply Wall St

Nov 02, 2024
pulisher
Nov 02, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes - MarketWatch

Nov 01, 2024
pulisher
Nov 01, 2024

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - Seeking Alpha

Nov 01, 2024
pulisher
Nov 01, 2024

Myriad Genetics (NASDAQ:MYGN) Shares Gap DownWhat's Next? - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Myriad Genetics (MYGN) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Assenagon Asset Management S.A. Reduces Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 28, 2024
pulisher
Oct 27, 2024

Myriad Genetics 2008A Retrospective - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Myriad Genetics Q4 Profit Declines, Yet Tops EstimateUpdate - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Myriad Genetics Swings to Q3 Profit - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Myriad Genetics Q1 Profit More Than Doubles, Yet Misses Estimate - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Making Peace With Rivals For A Slice Of BRCA... - RTTNews

Oct 27, 2024
pulisher
Oct 25, 2024

Relationship Tests Market Size 2024: Industry Overview, - openPR

Oct 25, 2024
pulisher
Oct 23, 2024

What We Don’t Know Can Hurt: New Survey Reveals Knowledge Gaps About Breast Density and Cancer Risk - North American Precis Syndicate, Inc.

Oct 23, 2024
pulisher
Oct 23, 2024

(MYGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 21, 2024

Myriad: Q2 Earnings Snapshot - Barchart

Oct 21, 2024
pulisher
Oct 18, 2024

Myriad Genetics Shares Fall Despite Partnership With jscreen - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

OmniStar Financial Group Inc. Makes New $863,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Direct-To-Consumer Genetic Testing Market to Grow by USD 1.22 Billion from 2024-2028, Driven by Early Disease Diagnosis and AI-Driven Market TransformationTechnavio - The Malaysian Reserve

Oct 17, 2024
pulisher
Oct 17, 2024

Myriad Genetics partners with jscreen for genetic testing By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 16, 2024

Myriad Genetics partners with jscreen for genetic testing - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

21,968 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Sanctuary Advisors LLC - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Myriad's MyRisk test integrated into Flatiron's OncoEMR - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Myriad's MyRisk test integrated into Flatiron's OncoEMR By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

Myriad Genetics and Flatiron Health Partner to Make Genetic - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration - StockTitan

Oct 15, 2024
pulisher
Oct 14, 2024

Cancer Genomic Testing Market – 37% of Growth to Originate from APAC -Myriad Genetics, Centogene AG, Color Genomics, Que – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

Scotiabank reiterates positive outlook on Myriad Genetics shares By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

SG Americas Securities LLC Takes $649,000 Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Global Consumer Genomics Market Huge Growth in Future Scope - openPR

Oct 14, 2024
pulisher
Oct 14, 2024

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Brokers Offer Predictions for Myriad Genetics, Inc.'s Q1 2025 Earnings (NASDAQ:MYGN) - MarketBeat

Oct 14, 2024
pulisher
Oct 12, 2024

Learn to Evaluate (MYGN) using the Charts - Stock Traders Daily

Oct 12, 2024
pulisher
Oct 11, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) CEO Sells 15,000 Shares - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) - GuruFocus.com

Oct 11, 2024
pulisher
Oct 11, 2024

Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock By Investing.com - Investing.com South Africa

Oct 11, 2024
pulisher
Oct 11, 2024

Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Insiders At Myriad Genetics Sold US$6.5m In Stock, Alluding To Potential Weakness - Simply Wall St

Oct 11, 2024

Myriad Genetics Inc Azioni (MYGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$218.80
price down icon 0.73%
diagnostics_research LH
$227.17
price up icon 0.03%
diagnostics_research WAT
$387.34
price up icon 0.03%
$153.49
price up icon 2.49%
diagnostics_research MTD
$1,364.02
price up icon 1.63%
$414.52
price down icon 0.66%
Capitalizzazione:     |  Volume (24 ore):